Cambridge, United States
Modalis Therapeutics, an emerging biotech company founded in 2016, is pioneering the development of therapeutics using CRISPR-based technology. The company's core offering revolves around its proprietary CRISPR-GNDM technology, which allows for precise gene expression and histone modification without DNA cleavage, gene editing, or base editing. This nuanced approach positions Modalis at the forefront of therapeutic solutions for orphan genetic diseases.
Headquartered in the United States, with R&D facilities in Cambridge and based in Tokyo, the firm is strategically placed in both key biotechnology hubs. Their last funding round was a Series B investment of $25.00M on April 10, 2019, attracting prominent investors such as SMBC Venture Capital, Mizuho Capital, and Pegasus Tech Ventures among others. The company’s momentum and strategic alliances underscore its potential as a pioneer in the biotechnology industry.
